Lymph Node Mapping Using Indocyanine Green Solution in Diagnosing Patients With Malignant Melanoma

Not Recruiting

Trial ID: NCT01898403

Age - 18 Years-N/A Condition - Skin (Cutaneous) Cancer, Skin - Melanoma Gender - All Accepting Healthy Volunteers - No

Purpose

This clinical trial compares and contrasts lymph node mapping using indocyanine green (IC-GREEN), isosulfan blue (ISB), and TSC and Lymphoscintigraphy with 99-technetium (99Tc) sulfur colloid (TSC). Study participants with malignant melanoma will undergo all 3 evaluations to assess the extent of the spread of the melanoma.

Official Title

Testing the Efficacy of Indocyanine Green Imaging (ICG-SPY) in the Identification of Sentinel Lymph Nodes (SLN) in Patients With Malignant Melanoma

Eligibility


Inclusion Criteria:

   - Ability to understand and willingness to sign informed consent document

   - Signed written informed consent

   - Malignant melanoma (MM) undergoing sentinel lymph node biopsy (SNLB)

   - 18 years of age or older

   - Complete blood count (CBC) and metabolic panel within 6 months

Exclusion Criteria:

   - History of hepatic or renal failure

   - Allergy to iodine containing products

   - Pregnant or may be pregnant

   - Psychiatric or addictive disorders that in the opinion of the research team, may not
   be able to meet study requirements

   - Undergoing dialysis

View More
View Less

Intervention(s):

drug: Isosulfan blue (ISB)

diagnostic test: Lymphoscintigraphy with 99-technetium (99Tc) sulfur colloid (TSC)

drug: indocyanine green solution

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Ralph S. Greco
650-736-1355

New Trial Alerts

©2024 Stanford Medicine